Danaher Corporation (DHR)

NYSE: DHR · IEX Real-Time Price · USD
250.28
+1.51 (0.61%)
Mar 28, 2024, 1:54 PM EDT - Market open
0.61%
Market Cap 184.02B
Revenue (ttm) 23.89B
Net Income (ttm) 4.74B
Shares Out 739.70M
EPS (ttm) 6.38
PE Ratio 39.13
Forward PE 32.40
Dividend $1.08 (0.43%)
Ex-Dividend Date Mar 27, 2024
Volume 947,076
Open 248.34
Previous Close 248.77
Day's Range 247.20 - 250.79
52-Week Range 182.09 - 259.00
Beta 0.86
Analysts Buy
Price Target 269.93 (+7.85%)
Earnings Date Apr 23, 2024

About DHR

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and service... [Read more]

Sector Healthcare
Founded 1969
Employees 63,000
Stock Exchange NYSE
Ticker Symbol DHR
Full Company Profile

Financial Performance

In 2023, Danaher's revenue was $23.89 billion, a decrease of -10.33% compared to the previous year's $26.64 billion. Earnings were $4.74 billion, a decrease of -33.23%.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $269.93, which is an increase of 7.85% from the latest price.

Price Target
$269.93
(7.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Danaher Schedules First Quarter 2024 Earnings Conference Call

WASHINGTON , March 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024 ...

6 days ago - PRNewsWire

Danaher to Present at TD Cowen Health Care Conference

WASHINGTON , Feb. 27, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conferen...

4 weeks ago - PRNewsWire

Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets

WASHINGTON , Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with ...

4 weeks ago - PRNewsWire

Danaher Announces Quarterly Dividend

WASHINGTON , Feb. 21, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common s...

5 weeks ago - PRNewsWire

Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expa...

7 weeks ago - PRNewsWire

Danaher forecasts revenue decline in 2024, shares fall

Life sciences firm Danaher forecast a low single-digit percentage decline year-over-year in its 2024 adjusted core revenue on Tuesday, sending the shares down nearly 4% before the bell.

2 months ago - Reuters

Danaher Reports Fourth Quarter and Full Year 2023 Results

WASHINGTON , Jan. 30, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2023.  All results in this release reflect only ...

2 months ago - PRNewsWire

Charts turn bullish on health-care stocks as sector takes early lead in 2024

Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts h...

2 months ago - Market Watch

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devast...

2 months ago - PRNewsWire

Danaher CEO to Comment on Financial Performance

WASHINGTON , Jan. 8, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Compan...

2 months ago - PRNewsWire

Danaher to Present at J.P. Morgan Healthcare Conference

WASHINGTON , Jan. 2, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P.

3 months ago - PRNewsWire

Investor Michael Farr is back with his top 10 stocks he's buying for 2024, and the tilt is defensive

This year's list is a bit more defensive than in years past and has a focus on earnings growth.

Other symbols: ABTAMZNDCIDISGSJNJMSFT
3 months ago - CNBC

Danaher Schedules Fourth Quarter 2023 Earnings Conference Call

WASHINGTON , Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 202...

3 months ago - PRNewsWire

Will Danaher Stock Rebound To Pre-Inflation Shock Highs Of $300?

Danaher stock (NYSE: DHR), a conglomerate with products in environmental, life sciences, and diagnostics fields, trades at $220 per share, about 2% below the level seen in March 2021. DHR stock was tr...

3 months ago - Forbes

Danaher completes $5.7 billion acquisition of Abcam

Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.

4 months ago - Reuters

Danaher Completes Acquisition of Abcam

WASHINGTON , Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for...

4 months ago - PRNewsWire

Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a def...

4 months ago - Business Wire

Danaher to Present at Evercore ISI HealthCONx Conference

WASHINGTON , Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf...

4 months ago - PRNewsWire

Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam today announced that all Identified Clearances required in connection with the acquisition of the company by Danaher have been obtained.

4 months ago - Business Wire

Abcam shareholders approve $5.7 billion Danaher deal

Abcam shareholders on Monday approved the proposal from Danaher Corp to acquire all outstanding shares of the company for $24 per share in cash.

5 months ago - Reuters

Shareholders of Abcam Approve Proposed Acquisition by Danaher

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Shareholders of Abcam approve proposed acquisition by Danaher.

5 months ago - Business Wire

Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign

Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc (“A...

5 months ago - GlobeNewsWire

Danaher appoints Christopher Riley to Executive Vice President for Biotechnology

WASHINGTON , Oct. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Rile...

5 months ago - PRNewsWire

Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.

Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.

5 months ago - Barrons

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same...

5 months ago - Market Watch